Revance to Participate in the JMP Securities Life Sciences Conference 2018
June 14 2018 - 4:05PM
Business Wire
Revance Therapeutics, Inc. (NASDAQ:RVNC), a biotechnology
company developing neuromodulators for use in treating aesthetic
and therapeutic conditions, today announced that the Company will
participate in the JMP Securities Life Sciences Conference 2018 in
New York, NY.
President and Chief Executive Officer, Dan Browne, is scheduled
to participate in a fireside chat on Wednesday, June 20 at 4:00pm
ET.
Interested parties can access the live audio webcast for this
conference from the Investor Relations section of the company's
website at www.revance.com. The webcast replay will be
available after the conclusion of the live presentation for
approximately 30 days.
About Revance Therapeutics, Inc.
Revance Therapeutics is a biotechnology company developing
neuromodulators for use in treating aesthetic and underserved
therapeutic conditions, including muscle movement disorders and
pain. The company's lead drug candidate, DaxibotulinumtoxinA for
Injection (RT002), is currently in development for the treatment of
glabellar lines, cervical dystonia and plantar fasciitis, with
plans to initiate studies in upper limb spasticity and chronic
migraine. RT002 has the potential to be the first long-acting
neuromodulator. Revance has developed a proprietary, stabilizing
excipient peptide technology designed to create novel,
differentiated therapies. The company has a comprehensive pipeline
based upon its peptide technology, including injectable and topical
formulations of daxibotulinumtoxinA. More information on Revance
may be found at www.revance.com.
"Revance Therapeutics" and the Revance logo are registered
trademarks of Revance Therapeutics, Inc.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20180614005009/en/
INVESTORSRevance Therapeutics, Inc.:Jeanie Herbert,
714-325-3584jherbert@revance.comorBurns McClellan, Inc.:Ami
Bavishi, 212-213-0006abavishi@burnsmc.comorMEDIAGeneral
Media:TOGORUN:Mariann Caprino,
917-242-1087m.caprino@togorun.comorTrade Media:Nadine Tosk,
504-453-8344nadinepr@gmail.com
Revance Therapeutics (NASDAQ:RVNC)
Historical Stock Chart
From Mar 2024 to Apr 2024
Revance Therapeutics (NASDAQ:RVNC)
Historical Stock Chart
From Apr 2023 to Apr 2024